TRex Bio Inc.
Trex Bio, Inc. engages in the manufacture of immunotherapies for autoimmune and inflammatory diseases. It focuses on studying the regulation of tissue inflammation to develop breakthrough medicines. The company was founded by Houman Ashrafian, Adil Daud, Wilson Liao, Diane Mathis, Drew Pardoll, Michael Rosenblum,…
1D
-1.1%
1W
+0.1%
1M
–
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
FREE FLOAT
–
FLOAT SHARES
–
AVG. DAILY VOLUME (30D)
357,182
Alexandria Venture Investments, LLC
Alexandria Venture Investments, LLC
SVLSF VI, LLC
SVLSF VI, LLC
SVLSF VI, LLC
TRex Bio Inc. is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in United States.
The CEO is Marion Johnston Erwin, the company employs around 60 people.
The IPO was on 09/10/2026; the stock trades on NASDAQ under the ticker TRXB.
No, TRex Bio currently does not pay a dividend.
Clicking "Analyze stock" lets five strategies assess TRex Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.